Panitumumab, sold under the brand name Vectibix, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as...
16 KB (1,421 words) - 15:40, 14 July 2024
nerve palsy Anti-cancer treatments such as erlotinib, cetuximab, and panitumumab, which block the function of EGFR (the epidermal growth factor receptor)...
3 KB (220 words) - 20:32, 27 August 2024
(FDA) updated the labels of two anti-EGFR monoclonal antibody drugs (panitumumab (Vectibix) and cetuximab (Erbitux)) indicated for treatment of metastatic...
26 KB (2,420 words) - 06:06, 17 August 2024
often[citation needed] combined with bevacizumab, aflibercept, cetuximab or panitumumab to improve efficacy and response rate. In the short term, irinotecan...
4 KB (411 words) - 21:05, 6 May 2024
2006: In April, Amgen acquired Abgenix, the developer of Vectibix (panitumumab), a treatment developed for certain patients with metastatic colorectal...
96 KB (7,736 words) - 20:56, 28 August 2024
As of 2006, KRAS mutation was predictive of a very poor response to panitumumab (Vectibix) and cetuximab (Erbitux) therapy in colorectal cancer. As of...
45 KB (5,079 words) - 06:39, 25 June 2024
mutation if it is combined with an anti-EGFR antibody such as cetuximab or panitumumab. Brigatinib is an inhibitor of ALK and mutated EGFR. ALK was first identified...
10 KB (796 words) - 12:29, 5 August 2024
Cetuximab Dostarlimab Gemtuzumab ozogamicin Ipilimumab Nivolumab Ofatumumab Panitumumab Pembrolizumab Ranibizumab Rituximab Trastuzumab Monoclonal antibodies...
49 KB (4,964 words) - 04:02, 9 August 2024
conventional antibodies like trastuzumab (targeting HER2/neu), cetuximab and panitumumab (both targeting the EGF receptor), using the BiTE approach. As of 2009[update]...
9 KB (1,471 words) - 05:56, 8 August 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab...
31 KB (3,430 words) - 05:24, 28 August 2024